Crispr Therapeutics Editas Medicine: Better Buy in 2026?
Two top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
Learn how to effectively engage in virtual networking for financial planners to expand your reach and connect with industry experts.
16,067 articlesTwo top gene-editing names, two very different strategies. This guide breaks down CRISPR Therapeutics and Editas Medi...
A line in SpaceX's draft filings has sparked market chatter for its sci-fi tone. The phrase elon musk slipped now dom...
A single-session jump can reveal more about value and risk than weeks of chatter. MGM Resorts stock jumps 16% after b...
A small-cap data services company sparked May’s AI rally, with Innodata surging nearly 150% after a solid earnings re...
May brought a sharp drop in oil markets as prices tumbled nearly 20%. This article breaks down what caused the move, ...
The White House has tapped a real-estate heir as acting director of national intelligence, a move that drew sharp que...
As investors chase high yields, the location of the account matters. In a taxable setup, $60,000 of ordinary-income d...
Lululemon is set to report its Q1 results tonight as margins, growth mix, and international exposure take center stag...
Actors ratified a four-year pact with studios and streaming platforms, securing pay raises and safeguards on AI usage...
FairGambling unveils a new crypto casino review and analytics platform combining on-chain insights, provably fair ver...
A senior executive at Twist BIOSCIENCE sold a sizable stake, sparking questions about insider activity. This article ...
As 2027 approaches, retirees wonder how big the Social Security COLA could be. This guide breaks down what to expect,...